Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GHSR | Q92847 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | APLNR | P35414 | 4/20 | 0.39 |
| ▸ | MMP3 | P08254 | 2/20 | 0.38 |
| ▸ | MMP8 | P22894 | 2/20 | 0.38 |
| ▸ | GPR6 | P46095 | 1/20 | 0.38 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4843151 | 0.92 | GHSR (0.41) | GHSRMAPTAPLNRMMP3MMP8 | |
| SCHEMBL4841794 | 0.85 | GHSR (0.42) | GHSRMAPTAPLNRGPR6TRPA1 | |
| SCHEMBL4833989 | 0.83 | TRPA1 (0.42) | MAPTTRPA1LMNANPSR1 | |
| SCHEMBL4833652 | 0.83 | MAPT (0.43) | GHSRMAPTMMP3MMP8LMNA | |
| SCHEMBL4842119 | 0.81 | MMP2 (0.41) | MAPTKMT2ALMNATP53TSHR | |
| SCHEMBL4834156 | 0.81 | CA12 (0.40) | GHSRMAPTAPLNRMMP3MMP8 | |
| SCHEMBL4843300 | 0.79 | TRPA1 (0.39) | GHSRMAPTMMP3MMP8TRPA1 | |
| SCHEMBL4837892 | 0.77 | GHSR (0.41) | GHSRMAPTAPLNRGPR6KMT2A | |
| SCHEMBL4836738 | 0.77 | ALDH1A1 (0.40) | MAPTKMT2ALMNA | |
| SCHEMBL4833640 | 0.76 | GHSR (0.41) | GHSRMAPTAPLNRGPR6TRPA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7465811-B2 | Indoline compounds | LABORATOIRES FOURNIER S.A. (FR) | 2008-12-16 | — | — | US | disclosed |
| US-20080119465-A1 | Novel Indoline Compounds | LABORATORIES FOURNIER S.A. (FR) | 2008-05-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080119465-A1 | Novel Indoline Compounds | GPR119, INSR, IRS1 | GHSR 251/4885MAPT 763/4885APLNR 1870/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.